Supernus Pharma Posts Profit In Q3, Ups Full Year Revenue View; Stock Climbs

(RTTNews) - Supernus Pharmaceuticals, Inc. (SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, said third-quarter net income was $27.9 million, or $0.39 per share, as compared to a net loss of $24.1 million, or $0.78 per share for the third quarter of 2013.

Adjusted loss was $2.04 million, while it totaled a loss of $19.94 million last year.

Total revenue for the quarter was $52.5 million, compared to $1.26 million in the prior year.

The latest revenue included $30.0 million in royalty monetization revenue. Net product revenue for Trokendi XR and Oxtellar XR was $22.5 million.

The company raised revenue guidance from around $105 million to a range of $115 million to $118 million for 2014.

SUPN, which closed down 2 percent on Tuesday at $7.91, climbed 6.8 percent in the extended trade.